Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases
Author:
Affiliation:
1. Pfizer Inc., Cambridge, Massachusetts 02139, United States
2. Pfizer Inc., Groton, Connecticut 06340, United States
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Link
https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c00948
Reference55 articles.
1. Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases
2. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
3. Emerging Topical and Systemic JAK Inhibitors in Dermatology
4. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition
5. Mechanisms of Jak/STAT Signaling in Immunity and Disease
Cited by 52 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Concise synthesis of pyridopyridazines;Tetrahedron Letters;2024-10
2. Small molecule drug discovery targeting the JAK-STAT pathway;Pharmacological Research;2024-06
3. Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases;Journal of Medicinal Chemistry;2024-05-28
4. TYK2: an emerging therapeutic target in rheumatic disease;Nature Reviews Rheumatology;2024-03-11
5. Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa;NEJM Evidence;2024-02-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3